GSK Glaxo Smith

Chloroquine (internal code 110027) is a small-molecule antimalarial agent developed by GlaxoSmithKline, formulated as chloroquine hydrochloride under the brand name ARALEN HYDROCHLORIDE. The drug acts as a ferriprotoporphyrin IX binding agent, disrupting parasite metabolism within red blood cells. It is administered by injection and represents a foundational antimalarial therapy with a long clinical history.

The program is currently in Phase 1 development status as of the latest milestone dated June 7, 2017. Chloroquine hydrochloride has already achieved regulatory approval in the United States under NDA006002, with Sanofi Aventis US listed as a sponsor on the approved formulation. This suggests GSK's Phase 1 program may represent a new formulation, indication expansion, or combination strategy rather than de novo development of the active pharmaceutical ingredient.

The malaria indication remains a significant global health priority, particularly in endemic regions of sub-Saharan Africa and Southeast Asia. GSK's continued investment in chloroquine development occurs within a competitive landscape that includes artemisinin-based combination therapies (ACTs) such as artemether-lumefantrine (Coartem) and emerging candidates like tafenoquine, also from GSK. The Phase 1 milestone in 2017 represents the most recent disclosed activity for this program.

Malaria remains a leading cause of morbidity and mortality in tropical and subtropical regions, with approximately 627,000 deaths reported annually as of recent WHO estimates. Drug-resistant Plasmodium falciparum strains have emerged in Southeast Asia and are spreading toward Africa, creating an urgent need for efficacious antimalarial agents with novel resistance profiles or optimized formulations.

Chloroquine, despite historical resistance issues in certain geographic regions, retains efficacy against chloroquine-sensitive strains and remains a first-line therapy in many endemic countries due to cost and accessibility. GSK's Phase 1 program may address formulation optimization, improved bioavailability, or combination strategies to enhance clinical utility. The competitive landscape includes multiple approved ACTs (artemether-lumefantrine, artesunate-amodiaquine) and GSK's own Phase 3 candidate tafenoquine, positioning chloroquine within a portfolio approach to antimalarial coverage.

The patient population spans endemic populations in Africa, Asia, and Latin America, with particular relevance in resource-limited settings where cost-effective, orally or parenterally administered therapies are essential. Commercial significance is tied to WHO procurement volumes, government malaria control programs, and humanitarian supply chains rather than traditional commercial markets. GSK's continued development suggests strategic value in maintaining or expanding market share within global health initiatives and ensuring supply security for this essential medicine.

Drug Class: Antimalarial, quinoline derivative

Mechanism of Action: Ferriprotoporphyrin IX binding agent; inhibits parasite heme polymerase, leading to accumulation of toxic heme and parasite death within infected erythrocytes

Modality: Small-molecule

Route of Administration: Injection (intravenous or intramuscular)

Target: Ferriprotoporphyrin IX (parasite heme metabolism pathway)

Molecular Target/Therapeutic Class: Plasmodium falciparum and other Plasmodium species

Related Therapies: Artemether-lumefantrine (Coartem), artesunate-amodiaquine, sulfadoxine-pyrimethamine, primaquine, amodiaquine, tafenoquine

Regulatory Status (US): Approved; chloroquine hydrochloride formulation (ARALEN HYDROCHLORIDE) holds NDA006002 with Sanofi Aventis US as sponsor

Patent Status: Not yet disclosed

United States: Chloroquine hydrochloride (ARALEN HYDROCHLORIDE) is approved under NDA006002, with Sanofi Aventis US listed as the regulatory sponsor. This approval predates the GSK Phase 1 program disclosed herein.

European Medicines Agency (EMA): Regulatory status not yet disclosed.

Pharmaceuticals and Medical Devices Agency (PMDA, Japan): Regulatory status not yet disclosed.

National Medical Products Administration (NMPA, China): Regulatory status not yet disclosed.

World Health Organization (WHO): Chloroquine remains on the WHO Essential Medicines List for malaria treatment in chloroquine-sensitive regions; specific prequalification status for GSK's formulation not yet disclosed.

The GSK Phase 1 program status (as of June 2017) suggests ongoing development activity distinct from the previously approved Sanofi formulation, potentially indicating a new formulation, combination product, or indication expansion under GSK sponsorship.

Strategic Positioning: GSK's continued Phase 1 development of chloroquine suggests a portfolio strategy to maintain or expand access to this essential medicine within global health markets rather than pursue commercial blockbuster potential. The injectable formulation addresses severe malaria, a distinct clinical niche from oral ACTs.

Competitive Implications: Chloroquine's Phase 1 status in 2017 indicates GSK is not abandoning older antimalarials despite the dominance of ACTs. This approach mirrors WHO guidance on maintaining multiple drug classes to mitigate resistance emergence and ensure treatment options across diverse epidemiological settings. GSK's tafenoquine (Phase 3) represents the company's innovation-focused antimalarial asset, while chloroquine serves a complementary access and supply security role.

Regulatory and Commercial Context: The pre-existing US approval (NDA006002) under Sanofi sponsorship indicates chloroquine's regulatory pathway is established. GSK's Phase 1 program likely targets formulation improvements, manufacturing optimization, or combination strategies rather than de novo efficacy or safety validation.

Future Catalysts: Potential milestones include Phase 1 completion, advancement to Phase 2 (if warranted), regulatory submissions for new formulations or combinations, and WHO prequalification. No expected next milestone date is currently disclosed.

Unmet Needs Addressed: Severe malaria requiring parenteral therapy, chloroquine-sensitive regions where cost and supply security are critical, and portfolio diversification to reduce dependence on artemisinin-based therapies in the context of emerging artemisinin resistance in Southeast Asia.